DUBLIN, July 1, 2013 /PRNewswire/ –PR Newswire (press release)The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the global top 20 best-selli…
Competitor Analysis: Biosimilar and Biosuperior Therapeutic AntibodiesPR Newswire UK (press release)This report provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next gen…
|
UPDATE: Piper Jaffray Raises PT on Biogen Idec on Multiple Positive Factors
Benzinga … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
Research and Markets: Novel Drugs to Drive Arthritis MarketWall Street Journal (press release)Other well-established therapies have also been allowed to keep their patents, including second-line RA treatment Actemra. However, patents are due to expire …
|
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment …
The Herald | HeraldOnline.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
Medical Daily |
European Agency Favors Remicade Biosimilars
MedPage Today Other biosimilars are available in Europe, such as Nivestim, which is similar to the granulocyte colony-stimulating factor analog filgrastim, and product-specific guidelines for monoclonal antibodies have been established by the medicines agency … ‘Biosimilar’ drug ruling to hit Big PharmaFinancial Times EMA’s CHMP backs approval of first two monoclonal antibody biosimilars of …The Pharma Letter A Pivotal Decision By European Drug Regulators on Remicade Is Unlikely To …Forbes Medical Daily –Philadelphia Business Journal –Bloomberg all 37 news articles » |
Medscape |
European Regulators Back Biosimilar Antibodies
Medscape This is notable because antibodies are inherently difficult to replicate and are subject to posttranslational modifications, such as glycosylation. They also may be heterogenous and often include subtle variants. Tight manufacturing controls … A Landmark For Biosimilars: EU Endorses Copies Of A J and J DrugForbes ‘Biosimilar’ drug ruling to hit Big PharmaFinancial Times Billion-dollar biotech drug may soon have biosimilar competitionPhiladelphia Business Journal Medical Daily –Businessweek –PipelineReview.com (press release) all 28 news articles » |
Medical Daily |
‘Biosimilar’ drug ruling to hit Big Pharma
Financial Times The decision is the first time in the industrialised world that the multibillion-dollar annual market for monoclonal antibodies has been opened to generic producers, after a long period during which investors assumed such complex “large molecule … European Agency Favors Remicade BiosimilarsMedPage Today First Copy of J&J’s $6 Billion Remicade Wins EMA BackingBloomberg A Pivotal Decision By European Drug Regulators on Remicade Is Unlikely To …Forbes The Pharma Letter –Medical Daily –PipelineReview.com (press release) all 37 news articles » |
Genzyme Receives Positive CHMP Opinion for LEMTRADA (alemtuzumab) in …PipelineReview.com (press release)CAMBRIDGE, MA, USA I June 28, 2013 I Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the Committee for Medicinal Pro…
KaloBios Provides Update on Pipeline of Clinical ProgramsPipelineReview.com (press release)SOUTH SAN FRANCISCO, CA, USA I June 27, 2013 I PRNewswire/ — KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of its ongoing…